We are live on ! Find out more
PAVMZ

PAVmed Inc. Series Z Warrant
PAVMZ

Delisted

PAVMZ was delisted on the 30th of April, 2025.

Back to rankings

3 hedge funds and large institutions have $858 invested in PAVmed Inc. Series Z Warrant in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

2,964% more capital invested

Capital invested by funds: $28 → $858 (+$830)

50% more funds holding

Funds holding: 2 → 3 (+1)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
3
Holders Change
+1
Holders Change %
+50%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$1.61K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$3
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$844 +$1.61K +42,208 New
UBS Group
2
UBS Group
Switzerland
$12 -$3 -80 -12%
Bank of America
3
Bank of America
North Carolina
$2 – – –

PAVMZ Hedge Fund Activity: Q2 2024 in Review

3 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in PAVmed Inc. Series Z Warrant (PAVMZ) for Q2 2024, worth a combined $858 — up 2,964% from $28 a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new PAVMZ positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $1.61K. The largest seller was UBS Group, cutting an estimated $3.

  • 3 institutional investors held PAVmed Inc. Series Z Warrant (PAVMZ) as of Q2 2024, up from 2 in Q1 2024.
  • Funds reported $858 of PAVmed Inc. Series Z Warrant stock for Q2 2024, up 2,964% quarter-over-quarter.
  • 1 fund opened new PAVmed Inc. Series Z Warrant positions in Q2 2024 and 0 closed out, a net change of +1 holder.
  • The largest PAVmed Inc. Series Z Warrant buyer in Q2 2024 was Citadel Advisors, an estimated $1.61K added.
  • The largest PAVmed Inc. Series Z Warrant seller in Q2 2024 was UBS Group, an estimated $3 sold.

Based on aggregated 13F filings for Q2 2024.